Amoxicillin

證據等級: L5

預測適應症: 8 個

Amoxicillin: From Bacterial Infections to Monoclonal Gammopathy (IPSID Subtype)

One-Sentence Summary

Amoxicillin is a broad-spectrum penicillin-class antibiotic used to treat a wide range of bacterial infections, including respiratory, urinary, and gastrointestinal tract infections. The TxGNN model predicts it may be relevant to Monoclonal Gammopathy — specifically the immunoproliferative small intestinal disease (IPSID) subtype, where chronic bacterial infection drives B-cell clonal expansion — with 1 clinical trial and 11 publications providing the strongest evidence base among all 8 predicted indications in this report. This prediction is biologically plausible but strictly limited to early-stage IPSID and cannot be extrapolated to MGUS, multiple myeloma, or Waldenström’s macroglobulinemia.

Quick Overview

Item	Content
Original Indication	Bacterial infections (standard antibiotic use; no regulatory license data available)
Predicted New Indication	Monoclonal Gammopathy (IPSID subtype)
TxGNN Prediction Score	99.22% (Rank 6 of 8 in predicted set; highest evidence level)
Evidence Level	L3
Canada Market Status	Not Marketed (0 licenses on file)
Number of DINs	0
Recommended Decision	Research Question

Note on prediction selection: Eight indications were predicted for this candidate (TW-DB01060-multi). Ranks 1–5 and rank 7 all carry L5 evidence with a “Hold” recommendation and no supporting clinical or preclinical data. Rank 6 (Monoclonal Gammopathy) is the highest-evidence prediction (L3) and is the focus of this report. Rank 8 (Septicemic Plague) carries L4 preclinical evidence and is summarised at the end.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Amoxicillin is a β-lactam antibiotic that inhibits bacterial cell wall synthesis by irreversibly binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking and triggering autolytic bacterial cell lysis. It provides broad-spectrum bactericidal activity against gram-positive cocci and many gram-negative organisms.

The connection to monoclonal gammopathy rests on a specific and well-characterised biological mechanism applicable only to IPSID (Immunoproliferative Small Intestinal Disease), also known as Mediterranean lymphoma or alpha heavy-chain disease. IPSID is an extranodal marginal zone B-cell lymphoma driven by chronic mucosal bacterial infection — most often Campylobacter jejuni and historically Helicobacter pylori — in which persistent bacterial antigen stimulation drives polyclonal, then oligoclonal, then monoclonal IgA heavy-chain-secreting B-cell expansion. Eliminating the bacterial antigen driver through antibiotic therapy can deprive the clonal population of its survival signal, enabling tumor regression in early-stage disease.

This mechanism is directly analogous to the well-established H. pylori eradication model for gastric MALT lymphoma, where triple therapy containing Amoxicillin + Clarithromycin + proton pump inhibitor achieves complete remission in up to 80% of early-stage cases. Multiple case reports — including a landmark 1997 Lancet publication (PMID 8988128) and a 2010 case series (PMID 20300878) — document IPSID regression following H. pylori eradication regimens. A 1996 Japanese case report (PMID 9030995) documents Mediterranean lymphoma treated successfully with antibiotics. This evidence base, while case-level only, provides mechanistic coherence that justifies a “Research Question” designation rather than an outright rejection.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00062231	NA	Terminated	351	Oral empirical antibiotic therapy (Amoxicillin/Clavulanic acid + Ciprofloxacin vs. Moxifloxacin monotherapy) for fever in low-risk neutropenic cancer patients. This is a supportive care study — the enrolled population includes hematologic cancer patients but the endpoint is infection control, not monoclonal gammopathy treatment. Trial was terminated early. Not interpretable as evidence for IPSID therapy. Relevance grade: C (peripheral).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
8988128	1997	Case Report / Retrospective Review	Lancet	Landmark case: Regression of IPSID after H. pylori eradication — direct evidence that antibiotic-based eradication therapy (Amoxicillin-containing triple therapy) can induce IPSID tumor regression.
9030995	1996	Retrospective Case Series	Internal Medicine (Tokyo)	Mediterranean lymphoma (IPSID) treated with antibiotics — a 74-year-old with IgA heavy-chain secreting lymphoplasmacytic infiltration responded to antibiotic treatment; supports the bacterial-antigen-driven model.
20300878	2010	Case Report / Retrospective Review	Journal of Gastrointestinal Cancer	Regression of IPSID after H. pylori eradication in a 20-year-old with extensive proximal small-bowel thickening and mesenteric lymphadenopathy — achieved remission following eradication therapy.
16253033	2005	Case Report	Archives of Pathology & Laboratory Medicine	Nonsecretory variant of IPSID — molecular and immunophenotypic characterisation of an extranodal marginal zone B-cell lymphoma; contextualises disease biology.
21908119	2011	Case Report	Médecine et Maladies Infectieuses	Pneumonia and Rothia dentocariosa in a haematology patient — Amoxicillin used for secondary bacterial infection; incidental to monoclonal gammopathy.
35619805	2022	Case Report	Frontiers in Public Health	Disseminated nocardiosis in a patient with macroglobulinemia — Amoxicillin/clavulanic acid listed as susceptible agent in antimicrobial sensitivity panel; Amoxicillin not used as primary treatment for macroglobulinemia.
20513124	2010	Diagnostic Accuracy Study	American Journal of Hematology	High false-positive Aspergillus galactomannan in multiple myeloma — context study in haematological malignancies; no direct Amoxicillin relevance.
18639371	2009	Retrospective Cohort	British Journal of Oral & Maxillofacial Surgery	Bisphosphonate-associated osteonecrosis of the jaw (ONJ) — Amoxicillin used as wound prophylaxis in myeloma patients; coincidental use.
20015614	2010	Case Series	International Journal of Oral and Maxillofacial Surgery	Surgical management of bisphosphonate-induced ONJ in 40 patients — Amoxicillin part of surgical antimicrobial protocol; not relevant to myeloma biology.
22092390	2012	Retrospective Comparative Cohort	Journal of Oral Pathology & Medicine	BRONJ comparison between multiple myeloma and breast cancer — Amoxicillin used as part of standardised ONJ management; no implications for monoclonal gammopathy treatment.

Evidence interpretation note: Of the 11 publications retrieved, only PMIDs 8988128, 9030995, 20300878, and 16253033 are directly relevant to the IPSID-antibiotic hypothesis. The remaining 7 publications document Amoxicillin used for infectious complications or surgical prophylaxis in patients who coincidentally have haematological malignancies — they do not constitute evidence for repurposing.

Safety Considerations

Safety data for this Evidence Pack has not been retrieved (Data Gap DG001: TFDA/Health Canada package insert warnings and contraindications pending). Please refer to the product package insert for complete prescribing information.

Based on well-established class knowledge:

Key Warnings: Serious and potentially fatal hypersensitivity (anaphylactic) reactions reported in patients receiving penicillin-class antibiotics; cross-reactivity with cephalosporins possible. Clostridioides difficile-associated diarrhoea (CDAD) can occur during and after antibiotic use.
Contraindications: History of serious hypersensitivity reaction (anaphylaxis or Stevens–Johnson syndrome) to any β-lactam antibiotic.

Conclusion and Next Steps

Decision: Research Question

Rationale: There is a mechanistically coherent and biologically grounded rationale for Amoxicillin (as part of H. pylori eradication triple therapy) in early-stage IPSID — a rare bacterial-antigen-driven B-cell lymphoproliferative disorder that closely parallels the established gastric MALT lymphoma eradication model. Landmark publications including a Lancet case report document genuine tumour regression. However, all current evidence consists of case reports and small series; no RCTs exist, the indication is narrowly disease-subtype specific, and the evidence does not support use in other monoclonal gammopathy variants.

To proceed, the following is needed:

Retrieve complete MOA data from DrugBank API (Data Gap DG002) to formally document PBP-binding mechanism and confirm no immunomodulatory off-target activity
Retrieve Health Canada / TFDA package insert for complete warnings and contraindications (Data Gap DG001)
Verify and correct market authorisation data — Amoxicillin is widely approved globally; the current “Not Marketed / 0 DINs” entry likely reflects a data collection gap
Commission a systematic review of IPSID antibiotic treatment literature to quantify response rates and identify optimal regimen composition (Amoxicillin alone vs. triple therapy combination)
Clarify whether the anti-tumour effect in IPSID is attributable to Amoxicillin specifically or to the triple-therapy combination (Amoxicillin + Clarithromycin + PPI)
Consult current haematology guidelines for IPSID staging criteria (Stage I–II vs. III) to define the patient population most likely to benefit
Consider prospective registry study or pilot trial in early-stage IPSID patients, particularly in regions of high IPSID prevalence (Middle East, North Africa, and South Asia)
Formally exclude this indication pathway for MGUS, multiple myeloma, Waldenström’s macroglobulinemia, and other non-IPSID monoclonal gammopathy subtypes

Appendix: Summary of All 8 Predicted Indications

| Rank | Disease | TxGNN Score | Evidence Level | Recommendation | Rationale Summary | |——|———|————|—————|—————-|——————-| | 1 | Polyclonal Hyperviscosity Syndrome | 99.63% | L5 | Hold | No mechanistic link; likely topological false positive from blood/infection node clustering in knowledge graph | | 2 | Hyperamylasemia | 99.63% | L5 | Hold | Laboratory marker, not a treatment target; Amoxicillin can paradoxically cause drug-induced pancreatitis | | 3 | Congenital Analbuminemia | 99.59% | L5 | Hold | Monogenic disease (ALB loss-of-function); no biological rationale for antibiotic intervention | | 4 | Blood Group Incompatibility | 99.40% | L5 | Hold | Sole literature finding (PMID 40350274) is a coincidental Campylobacter bacteraemia in an ABO-mismatched HSCT patient — Amoxicillin treated an infection, not the incompatibility | | 5 | Premalignant Haematological System Disease | 99.29% | L5 | Hold | MDS/CHIP/SMM require targeted or watch-and-wait strategies; no antibiotic mechanism relevant | | 6 | Monoclonal Gammopathy (IPSID) | 99.22% | L3 | Research Question | Biologically plausible for IPSID subtype; H. pylori eradication therapy (Amoxicillin-containing) documented to induce IPSID regression — see full report above | | 7 | Haematological Disease with Acquired Peripheral Neuropathy | 99.14% | L5 | Hold | Paraprotein/amyloid-driven neuropathies (POEMS, AL) require targeted blood disorder therapy; no antibiotic mechanism | | 8 | Septicemic Plague | 99.13% | L4 | Research Question | In vitro and murine studies show β-lactam activity against Y. pestis; however, clinical guidelines recommend aminoglycosides or fluoroquinolones as first-line due to β-lactamase resistance concerns and intracellular penetration limitations |

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.